Helix Biomedix Stock Price Prediction
| HXBM Stock | USD 2.00 0.00 0.00% |
Momentum 0
Sell Peaked
Oversold | Overbought |
Using Helix BioMedix hype-based prediction, you can estimate the value of Helix BioMedix from the perspective of Helix BioMedix response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Helix BioMedix to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Helix because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Helix BioMedix after-hype prediction price | USD 2.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Helix |
Helix BioMedix After-Hype Price Prediction Density Analysis
As far as predicting the price of Helix BioMedix at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Helix BioMedix or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Helix BioMedix, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Helix BioMedix Estimiated After-Hype Price Volatility
In the context of predicting Helix BioMedix's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Helix BioMedix's historical news coverage. Helix BioMedix's after-hype downside and upside margins for the prediction period are 0.10 and 6.09, respectively. We have considered Helix BioMedix's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Helix BioMedix is very risky at this time. Analysis and calculation of next after-hype price of Helix BioMedix is based on 3 months time horizon.
Helix BioMedix Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Helix BioMedix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Helix BioMedix backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Helix BioMedix, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.78 | 4.13 | 0.00 | 0.06 | 0 Events / Month | 0 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.00 | 2.00 | 0.00 |
|
Helix BioMedix Hype Timeline
Helix BioMedix is currently traded for 2.00. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.06. Helix is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at -0.78%. %. The volatility of related hype on Helix BioMedix is about 5506.67%, with the expected price after the next announcement by competition of 1.94. The book value of the company was currently reported as 6.94. The company recorded a loss per share of 15.59. Helix BioMedix had not issued any dividends in recent years. The entity had 1:300 split on the 3rd of January 2013. Given the investment horizon of 90 days the next forecasted press release will be in a few days. Check out Helix BioMedix Basic Forecasting Models to cross-verify your projections.Helix BioMedix Related Hype Analysis
Having access to credible news sources related to Helix BioMedix's direct competition is more important than ever and may enhance your ability to predict Helix BioMedix's future price movements. Getting to know how Helix BioMedix's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Helix BioMedix may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ORGS | Orgenesis | (0.75) | 1 per month | 47.78 | 0.20 | 493.33 | (85.00) | 4,994 | |
| BPTH | Bio Path Holdings | 0.00 | 0 per month | 7.16 | 0.06 | 16.67 | (14.29) | 55.56 | |
| EMMA | Emmaus Life Sciences | 0.00 | 0 per month | 7.48 | 0.07 | 27.59 | (15.45) | 64.24 | |
| SQZB | SQZ Biotechnologies | 0.00 | 0 per month | 0.00 | (0.02) | 7.69 | (9.80) | 50.43 | |
| CNTRF | Centr Brands Corp | 0.00 | 0 per month | 0.00 | 0.07 | 0.00 | (9.09) | 289.02 | |
| SYBE | SYBLEU INC | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PAIOF | Paion AG | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NSTM | Hollywood Media Co | 0.00 | 0 per month | 0.00 | 0.06 | 0.00 | 0.00 | 100.00 | |
| NGMC | Next Generation Management | 0.00 | 0 per month | 16.87 | 0.13 | 50.00 | (33.33) | 213.33 | |
| NTRR | Neutra Corp | 0.00 | 0 per month | 19.20 | 0.13 | 100.00 | (50.00) | 150.00 |
Helix BioMedix Additional Predictive Modules
Most predictive techniques to examine Helix price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Helix using various technical indicators. When you analyze Helix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Helix BioMedix Predictive Indicators
The successful prediction of Helix BioMedix stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Helix BioMedix, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Helix BioMedix based on analysis of Helix BioMedix hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Helix BioMedix's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Helix BioMedix's related companies.
Story Coverage note for Helix BioMedix
The number of cover stories for Helix BioMedix depends on current market conditions and Helix BioMedix's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Helix BioMedix is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Helix BioMedix's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Other Information on Investing in Helix Pink Sheet
Helix BioMedix financial ratios help investors to determine whether Helix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioMedix security.